Investor Hub

Novavax is a global biotechnology company with a proven vaccine technology. We are focused on developing our R&D assets and establishing partnerships to leverage the value of our technology to help protect health.

Latest quarterly earnings
Download PDF
Latest investor presentation
Download PDF
Latest clinical presentation
Download PDF
Annual report
Download PDF
Latest publications
See our research
Pipeline
View the latest pipeline
NASDAQ:NVAX
Loading data...
Stock details
Latest press releasesEvents & presentationsReports & financialsSEC filingsStock details & analyst coverage
Stock details

Loading data...

 

Historical stock price

Analyst coverage
Mayank Mamtani
B. Riley FBR
Alec Stranahan, PhD
BofA Securities
Tom Shrader, PhD, CFA
BTIG
Vernon Bernardino
H.C. Wainwright & Co.
Roger Song, MD, CFA
Jefferies
Eric Joseph, PhD
JP Morgan
Chris LoBianco
TD Cowen

The analysts listed on this page follow Novavax. Please note that any opinions, estimates or forecasts regarding Novavax' performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Novavax or its management. Novavax does not by its reference above or distribution imply its endorsements of or concurrence with such information, conclusions or recommendations.

Governance documents
Get notifications for investor updates

Sign up for notifications from Novavax including upcoming events, webcasts, research updates, daily stock closings, SEC filings and more.

Shareholders seeking information can contact investor relations at (240) 268-2022 or contact us. 

Novavax corporate policy prohibits any employees, other than designated spokespersons, from communicating with its investors.

Go to email subscription